Regulatory
Hutchison China MediTech Limited will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm Hong Kong Time (HKT); 2:00 am Eastern Daylight Time (EDT)).
Shares of Karyopharm Therapeutics have skyrocketed more than 36% after the U.S. Food and Drug Administration approved the Newton, Mass.-based company’s treatment for multiple myeloma.
As fireworks illuminate the night skies across the United States this weekend in celebration of Independence Day, BioSpace takes a look at some of the highlights of the pharma industry from the first half of 2019 and earlier that provides millions of patients with the independence of health.
Facebook, YouTube and other sites are changing protocols regarding posts that contain information about misleading medical treatments.
The latest clinical hold was placed after a patient experienced serious adverse events that included neurotoxicity and cytomegalovirus infection, as well as severe respiratory distress.
In addition to the states agreeing to pause lawsuits, the FDA accepted Insys’ NDA for an opioid overdose medication.
Fusion Antibodies plc announces its final results for the year ended 31 March 2019.
Patented technology applied in SynGEM, a needle-free nasal spray vaccine against respiratory syncytial virus * Re-Issuance of U.S. Patent No. RE 47,471 further bolsters Mucosis’ intellectual property portfolio
BioArctic AB to publish the company’s Interim Report for the period January – June 2019 on Thursday, July 11, 2019 at 08:00 a.m. CET.
Only days after it was announced that Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration (FDA), was joining Pfizer’s board of directors, presidential hopeful Senator Elizabeth Warren (D-Mass) called for him to resign from the position.
PRESS RELEASES